These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

388 related items for PubMed ID: 11593388

  • 21. Suppression of interleukin-3-induced gene expression by a C-terminal truncated Stat5: role of Stat5 in proliferation.
    Mui AL, Wakao H, Kinoshita T, Kitamura T, Miyajima A.
    EMBO J; 1996 May 15; 15(10):2425-33. PubMed ID: 8665850
    [Abstract] [Full Text] [Related]

  • 22. BCR/ABL and IL-3 activate Rap1 to stimulate the B-Raf/MEK/Erk and Akt signaling pathways and to regulate proliferation, apoptosis, and adhesion.
    Jin A, Kurosu T, Tsuji K, Mizuchi D, Arai A, Fujita H, Hattori M, Minato N, Miura O.
    Oncogene; 2006 Jul 20; 25(31):4332-40. PubMed ID: 16518411
    [Abstract] [Full Text] [Related]

  • 23. Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL.
    Amarante-Mendes GP, McGahon AJ, Nishioka WK, Afar DE, Witte ON, Green DR.
    Oncogene; 1998 Mar 20; 16(11):1383-90. PubMed ID: 9525737
    [Abstract] [Full Text] [Related]

  • 24. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q, Lu Z, Chen Q, Lai Y, Pan J.
    Clin Cancer Res; 2009 Mar 01; 15(5):1686-97. PubMed ID: 19240172
    [Abstract] [Full Text] [Related]

  • 25. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
    Gross AW, Ren R.
    Oncogene; 2000 Dec 14; 19(54):6286-96. PubMed ID: 11175343
    [Abstract] [Full Text] [Related]

  • 26. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia.
    Shuai K, Halpern J, ten Hoeve J, Rao X, Sawyers CL.
    Oncogene; 1996 Jul 18; 13(2):247-54. PubMed ID: 8710363
    [Abstract] [Full Text] [Related]

  • 27. Prostate apoptosis response gene-4 (par-4) abrogates the survival function of p185(BCR-ABL) in hematopoietic cells.
    Kukoc-Zivojnov N, Puccetti E, Chow KU, Bergmann M, Ruthardt M, Hoelzer D, Mitrou PS, Weidmann E, Boehrer S.
    Exp Hematol; 2004 Jul 18; 32(7):649-56. PubMed ID: 15246161
    [Abstract] [Full Text] [Related]

  • 28. CML and apoptosis: the ceramide pathway.
    Maguer-Satta V.
    Hematol Cell Ther; 1998 Oct 18; 40(5):233-6. PubMed ID: 9844818
    [Abstract] [Full Text] [Related]

  • 29. Phosphatidylinositol 3-kinase (PI-3K)/Akt but not PI-3K/p70 S6 kinase signaling mediates IGF-1-promoted lens epithelial cell survival.
    Chandrasekher G, Sailaja D.
    Invest Ophthalmol Vis Sci; 2004 Oct 18; 45(10):3577-88. PubMed ID: 15452065
    [Abstract] [Full Text] [Related]

  • 30. Adhesion to fibronectin selectively protects Bcr-Abl+ cells from DNA damage-induced apoptosis.
    van der Kuip H, Goetz AW, Miething C, Duyster J, Aulitzky WE.
    Blood; 2001 Sep 01; 98(5):1532-41. PubMed ID: 11520804
    [Abstract] [Full Text] [Related]

  • 31. [Effect on bcr-abl signaling pathway and the mechanisms of apoptosis induction by meisoindigo in K562 cells].
    Liu BC, Xiao ZJ.
    Zhonghua Xue Ye Xue Za Zhi; 2008 Dec 01; 29(12):815-8. PubMed ID: 19176035
    [Abstract] [Full Text] [Related]

  • 32. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL.
    Adam M, Pogacic V, Bendit M, Chappuis R, Nawijn MC, Duyster J, Fox CJ, Thompson CB, Cools J, Schwaller J.
    Cancer Res; 2006 Apr 01; 66(7):3828-35. PubMed ID: 16585210
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Immunoreactivity of Stat5 phosphorylated on tyrosine as a cell-based measure of Bcr/Abl kinase activity.
    Jacobberger JW, Sramkoski RM, Frisa PS, Ye PP, Gottlieb MA, Hedley DW, Shankey TV, Smith BL, Paniagua M, Goolsby CL.
    Cytometry A; 2003 Aug 01; 54(2):75-88. PubMed ID: 12879454
    [Abstract] [Full Text] [Related]

  • 36. [Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].
    Müller-Tidow C, Steur C, Mizuki M, Schwäble J, Brandts C, Berdel WE, Serve H.
    Dtsch Med Wochenschr; 2002 Oct 18; 127(42):2195-200. PubMed ID: 12397548
    [Abstract] [Full Text] [Related]

  • 37. p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines.
    Okuda K, Golub TR, Gilliland DG, Griffin JD.
    Oncogene; 1996 Sep 19; 13(6):1147-52. PubMed ID: 8808688
    [Abstract] [Full Text] [Related]

  • 38. Complementary functions of the antiapoptotic protein A1 and serine/threonine kinase pim-1 in the BCR/ABL-mediated leukemogenesis.
    Nieborowska-Skorska M, Hoser G, Kossev P, Wasik MA, Skorski T.
    Blood; 2002 Jun 15; 99(12):4531-9. PubMed ID: 12036885
    [Abstract] [Full Text] [Related]

  • 39. Role of p21(WAF1/CIP1) as an attenuator of both proliferative and drug-induced apoptotic signals in BCR-ABL-transformed hematopoietic cells.
    Forster K, Obermeier A, Mitina O, Simon N, Warmuth M, Krause G, Hallek M.
    Ann Hematol; 2008 Mar 15; 87(3):183-93. PubMed ID: 17960378
    [Abstract] [Full Text] [Related]

  • 40. FAK silencing inhibits leukemogenesis in BCR/ABL-transformed hematopoietic cells.
    Le Y, Xu L, Lu J, Fang J, Nardi V, Chai L, Silberstein LE.
    Am J Hematol; 2009 May 15; 84(5):273-8. PubMed ID: 19358301
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.